{xtd_wp_head}
Keywords: Biotechnology, Disease Treatment
Epithelial ovarian cancer is the 5th leading cancer among women, with a 49% five-year survival rate. Current treatment strategies for ovarian cancer include surgical removal, chemotherapy, and radiation; however, these treatments often prove ineffective or toxic to patients. Global News Wire expects the nanotechnology drug delivery market to have an 18.7% CAGR growth rate from 2022 to 2032. Current chemotherapies are limited due to the toxicity of therapeutic and resistance to treatment. Furthermore, there has been increased attention to reducing systemic effects and therapeutic concentration. This technology fills this gap by providing an effective delivery platform for RNA interference (RNAi) therapeutics, a mechanism that can be used to silence oncogenes responsible for cancer progression. While a promising strategy for treatment, RNAi cargo requires an efficient delivery system to improve its bioavailability and delivery into cancer cells. Clemson University researchers have developed novel fusogenic peptides that facilitate efficient uptake and endosomal escape of RNAi therapeutics in ovarian cancer cells, resulting in enhanced bioactivity and therapeutic efficacy.
Gene silencing for cancer treatment
The peptides' design is composed of alternating residues of hydrophobic and hydrophilic amino acids, highlighted by repeating aspartic acid residues. Due to the inclusion of a cationic tail, these peptides have shown effective electrostatic complexation and protection of RNAi cargo. High biocompatibility and cellular internalization have been shown both in vitro and in vivo. These sequences have proven to enhance endosomal escape through the protonation of hydrophobic amino acids, which leads to a conformational change in a more acidic pH to disrupt the endosomal membrane. Upon release from the endosome, the siRNA is released into the cytoplasm of the cell, where it is bioactive. Due to this enhanced cytoplasmic delivery, gene silencing studies have proven the system's significant efficacy in silencing the target oncogene, resulting in significant antitumor activity in vivo. Therefore, these novel peptides demonstrate a highly efficient delivery system for RNAi therapeutic applications for cancer treatment.
Preclinical and invivo proof of concept
PCT
US2023/061436
2021-025
Dr. Angela Alexander-Bryant Dr. Timothy Samec
A. Chris Gesswein
Executive Director
E: agesswe@clemson.edu
P: (864) 656-0797
Contact
Stay up-to-date with the latest trends in the innovation and research industry. Sign up for our newsletter to see how CURF is making a difference and impacting the economy where we live.